NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

EYEN

Eyenovia Inc

Jun 20 • 04:00PM ET

4.21

Dollar change -0.62
Percentage change -12.84	%

Healthcare • Biotechnology • USA • NASD

Peers: ALDX OCUL EDIT KALA XERS NCNA PRPH CRVS PRQR OPTN

| Held by: VXF BTEC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-44.81	Insider Own	2.26%	Shs Outstand	2.83M	Perf Week	57.68%
Market Cap	12.14M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	2.82M	Perf Month	152.10%
Enterprise Value	19.38M	PEG	-	EPS next Q	-	Inst Own	23.71%	Short Float	5.91%	Perf Quarter	192.36%
Income	-42.38M	P/S	173.43	EPS this Y	-	Inst Trans	0.62%	Short Ratio	0.05	Perf Half Y	-35.51%
Sales	0.07M	P/B	-	EPS next Y	-	ROA	-263.55%	Short Interest	0.17M	Perf YTD	-63.96%
Book/sh	-3.43	P/C	3.09	EPS next 5Y	-	ROE	-388.03%	52W Range	0.85 - 124.80	Perf Year	-91.79%
Cash/sh	1.36	P/FCF	-	EPS past 3/5Y	-15.48% 12.70%	ROIC	-	52W High	-96.63%	Perf 3Y	-97.20%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-84.00% -	Gross Margin	-6754.50%	52W Low	395.29%	Perf 5Y	-98.35%
Dividend TTM	-	EV/Sales	276.86	EPS Y/Y TTM	25.89%	Oper. Margin	-40901.24%	Volatility	53.08% 28.91%	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.34	Sales Y/Y TTM	663.82%	Profit Margin	-63194.11%	RSI (14)	56.64	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.34	EPS Q/Q	91.51%	SMA20	39.77%	Beta	1.00	Target Price	2.00
Payout	-	Debt/Eq	-	Sales Q/Q	194.81%	SMA50	124.10%	Rel Volume	0.74	Prev Close	4.83
Employees	14	LT Debt/Eq	-	Earnings	May 19 AMC	SMA200	-68.28%	Avg Volume	3.14M	Price	4.21
IPO	Jan 25, 2018	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	2,314,677	Change	-12.84%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-18-24	Downgrade	H.C. Wainwright	Buy → Neutral	$12 → $2
Mar-01-21	Initiated	Northland Capital	Outperform	$10
Feb-03-20	Downgrade	Oppenheimer	Outperform → Perform

Jun-18-25 02:04PM	Chardan Expands into Digital Assets by Advising Strategic Crypto-Backed Financings (PR Newswire) -30.70%
08:32AM	Eyenovia Announces Appointment of a Strategic Advisor for Digital Asset Treasury Strategy and Amendment of Debt Agreement with Avenue Capital Group (GlobeNewswire)
Jun-17-25 02:55PM	Eyenovia Announces $50 Million Investment to Launch a Hyperliquid (HYPE token) Cryptocurrency Treasury Reserve Strategy (GlobeNewswire) +134.68%
May-19-25 05:30PM	Eyenovia Provides Updates on Potential Merger with Betaliq and Development of the Optejet User Filled Device (UFD), and Reports First Quarter 2025 Financial Results (GlobeNewswire) +47.79%
Apr-10-25 07:00AM	Eyenovia Provides Development Update on Optejet User Filled Device (UFD) (GlobeNewswire)
03:11PM	Loading…
Mar-20-25 03:11PM	Eyenovia Shares Drop 14% Amid Betaliq Merger Talks (GuruFocus.com) -13.77%
10:24AM	Eyenovia falls on plans to seek reverse merger (SeekingAlpha)
07:00AM	Eyenovia Enters into Non-Binding Letter of Intent to Effect Reverse Merger with Betaliq (GlobeNewswire)
Feb-26-25 07:00AM	Eyenovia Regains Compliance with All Nasdaq Continued Listing Requirements (GlobeNewswire) +16.56%
Feb-24-25 07:00AM	Eyenovia, Inc. Announces Debt Restructuring Including Amendment to Senior Secured Debt, Improving Cash Runway to Allow for the Evaluation of Strategic Alternatives (GlobeNewswire) -5.36%
Feb-05-25 07:00AM	Eyenovia Announces Progress on Next-Generation User-Filled Optejet Dispensing Device (GlobeNewswire) -12.82%
Jan-28-25 04:05PM	Eyenovia Announces 1-for-80 Reverse Stock Split (GlobeNewswire) -34.74%
Jan-15-25 07:00AM	Eyenovia Announces Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend Eyenovia Stockholders Vote FOR Proposed Reverse Stock Split at Upcoming Special Meeting of Stockholders (GlobeNewswire) -23.37%
Jan-06-25 07:00AM	Eyenovia Engages Chardan as Advisor for Review of Strategic Alternatives (GlobeNewswire) +9.17%
Dec-06-24 08:00AM	Eyenovia, Inc. Announces Pricing of $1.9 Million Registered Direct Offering (GlobeNewswire) -9.49%
08:00AM	Loading…
Nov-25-24 08:00AM	Eyenovia, Inc. Announces Pricing of $1.3 Million Registered Direct Offering (GlobeNewswire) -17.38%
Nov-23-24 07:05AM	Eyenovia taking additional actions to reduce personnel-related costs by over 70% (TipRanks)
Nov-22-24 07:00AM	Eyenovia Provides Update on Restructuring Efforts (GlobeNewswire)
Nov-19-24 06:15AM	Eyenovia downgraded to Neutral from Buy at H.C. Wainwright (TipRanks) +7.39%
Nov-18-24 07:38AM	Eyenovia stock plummets following Phase III myopia trial failure (Clinical Trials Arena) +8.93%
Nov-15-24 01:15PM	Eyenovia Stock Sinks As Pivotal Trial Fails To Hit Primary Efficacy Goal, Analyst Downgrades Due To Limited Capital And Near Term Upside From Pipeline (Benzinga) -70.04%
07:00AM	Eyenovia Provides Update on Phase 3 CHAPERONE Study (GlobeNewswire)
Nov-13-24 02:17AM	Eyenovia Inc (EYEN) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges (GuruFocus.com) -19.35%
Nov-12-24 05:45PM	Eyenovia, Inc. (EYEN) Reports Q3 Loss, Misses Revenue Estimates (Zacks) +8.85%
04:05PM	Eyenovia Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-07-24 07:00AM	Eyenovia to Report Third Quarter 2024 Results on Tuesday, November 12th (GlobeNewswire)
Oct-23-24 07:00AM	Eyenovia Announces Publication of Study Demonstrating Favorable Impact on the Ocular Surface of Medication Delivered with the Optejet (GlobeNewswire)
Oct-16-24 07:00AM	Eyenovia Announces Presentation of Phase 3 Clobetasol Study Results at the American Academy of Ophthalmology (AAO) 2024 Expo (GlobeNewswire) +22.17%
Oct-14-24 09:55AM	Here's Why Eyenovia (EYEN) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Oct-09-24 06:13PM	Eyenovia Inc (EYEN) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges (GuruFocus.com)
07:00AM	Loading…
Oct-01-24 07:00AM	Eyenovia Announces Commencement of Manufacturing of its Advanced, Second Generation Optejet Device (GlobeNewswire)
Sep-27-24 08:30AM	Eyenovia, Inc. Announces Pricing of $4 Million Registered Direct Offering (GlobeNewswire) +6.93%
Sep-26-24 07:00AM	Eyenovia Announces Launch and Commercial Availability of Clobetasol Propionate Ophthalmic Suspension 0.05% for Post-Operative Inflammation and Pain Following Ocular Surgery (GlobeNewswire)
Sep-09-24 06:53AM	Formosa Pharma ships APP13007 ophthalmic drug to US (Pharmaceutical Technology) +14.35%
03:00AM	Formosa Pharmaceuticals Makes First Shipment of APP13007 (Clobetasol Propionate Ophthalmic Suspension, 0.05%) to the United States for Commercialization (PR Newswire)
Sep-05-24 07:00AM	Eyenovia Announces Taiwan Export License Approval to Commence Shipment of Clobetasol Propionate Ophthalmic Suspension (0.05%) to the U.S. (GlobeNewswire)
Sep-03-24 07:00AM	Eyenovia Announces Appointment of Experienced Finance and Accounting Executive Andrew Jones as Chief Financial Officer (GlobeNewswire)
Aug-23-24 11:42AM	Eyenovia Announces Closing of Public Offering (GlobeNewswire) +6.53%
Aug-21-24 09:29AM	Eyenovia Announces Pricing of $5.14 Million Public Offering (GlobeNewswire) -31.64%
Aug-20-24 05:09PM	Eyenovia, Inc. Announces Proposed Public Offering (GlobeNewswire) -17.03%
Aug-15-24 12:00PM	Eyenovia (EYEN) Upgraded to Buy: Here's What You Should Know (Zacks)
Aug-13-24 07:00AM	Eyenovia to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference (GlobeNewswire) -9.08%
Aug-12-24 05:30PM	Eyenovia, Inc. (EYEN) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Eyenovia Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-08-24 07:00AM	Eyenovia to Report Second Quarter 2024 Results on Monday, August 12th (GlobeNewswire) -6.16%
Aug-07-24 05:11PM	Eyenovia and Formosa Pharmaceuticals Initiate Co-Development of Clobetasol Propionate Ophthalmic Suspension (0.05%) for the Treatment of Acute Dry Eye Disease in the U.S. (GlobeNewswire)
08:00AM	Formosa Pharma and Eyenovia Announce Initiation of Co-Development of Clobetasol Propionate Ophthalmic Suspension, 0.05%, for the treatment of Acute Dry Eye Disease in United States (PR Newswire)
Jul-30-24 08:00AM	Eyenovia & SGN Nanopharma Announce Collaboration Agreement to Develop Novel Treatment for Chronic Dry Eye Disease (GlobeNewswire)
Jul-23-24 07:00AM	Eyenovia and Senju Pharmaceutical Co., Ltd. Sign Collaboration Agreement for Potential New Treatment for Chronic Dry Eye Disease (GlobeNewswire) +14.17%
Jul-01-24 06:50AM	NovaBay Pharmaceuticals and Eyenovia Commence Co-Promotion Activities (Business Wire) +14.27%
Jun-28-24 08:00AM	Eyenovia Announces Pricing of $5M Registered Direct Offering (GlobeNewswire) -14.16%
May-23-24 06:00AM	Peek Behind the Curtain: 7 Penny Stocks With Heavy Insider Buying (InvestorPlace) -7.49%
May-20-24 12:00PM	All You Need to Know About Eyenovia (EYEN) Rating Upgrade to Buy (Zacks)
May-16-24 03:07AM	Eyenovia Inc (EYEN) (Q1 2024) Earnings Call Transcript Highlights: Navigating Challenges and ... (GuruFocus.com) -22.56%
May-15-24 08:55PM	EYEN Stock Earnings: Eyenovia Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace) +28.28%
04:01PM	Eyenovia Reports First Quarter 2024 Financial Results and Provides Updates on its Myopia Phase III Program and its Two FDA Approved Commercial Products, Mydcombi and Clobetasol (GlobeNewswire)
May-14-24 07:00AM	Eyenovia to Report First Quarter 2024 Results on Wednesday, May 15th (GlobeNewswire)
May-10-24 06:31AM	Formosa and Tabuk sign deal for FDA-approved ophthalmic suspension (Pharmaceutical Technology)
Apr-25-24 07:00AM	Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi and Clobetasol Propionate Ophthalmic Suspension (GlobeNewswire) +21.90%
Apr-09-24 09:29AM	Eyenovia (EYEN) Down 18% on Disappointing Corporate Update (Zacks) -15.73%
Apr-08-24 07:00AM	Eyenovia Announces Updated Strategy and Corporate Priorities to Focus on Shareholder Value Generation and Immediate Commercial Opportunities (GlobeNewswire) -17.99%
Apr-03-24 07:00AM	Eyenovia to Feature its Suite of Commercial Products and the Optejet Dispenser at Upcoming National Eyecare Meetings (GlobeNewswire) -6.63%
Mar-27-24 11:28AM	NovaBay Pharmaceuticals, Inc. (AMEX:NBY) Q4 2023 Earnings Call Transcript (Insider Monkey)
09:57AM	Q4 2023 NovaBay Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-19-24 08:50AM	Eyenovia, Inc. (NASDAQ:EYEN) Q4 2023 Earnings Call Transcript (Insider Monkey) -23.20%
06:41AM	Q4 2023 Eyenovia Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-18-24 08:53PM	EYEN Stock Earnings: Eyenovia Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace)
05:20PM	Eyenovia, Inc. (EYEN) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Eyenovia Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Mar-13-24 07:00AM	NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals (GlobeNewswire)
Mar-11-24 07:00AM	Eyenovia to Report Fourth Quarter 2023 Results and Provide Business Update on Monday, March 18th (GlobeNewswire)
Mar-05-24 12:59PM	Beyond Cataract Surgery: Analyst Highlights Broader Market Potential For Eyenovia/Formosa's Steroid For Post-Eye Surgery Pain, Inflammation (Benzinga) -22.81%
08:00AM	Eyenovia Congratulates Formosa Pharmaceuticals on FDA Approval of Clobetasol Propionate Ophthalmic Suspension 0.05% for the Treatment of Post-operative Inflammation and Pain Following Ocular Surgery (GlobeNewswire)
Mar-04-24 06:21PM	UPDATE 2-US FDA approves Eyenovia's eye drug, Formosa Pharma says (Reuters)
06:06PM	US FDA approves Eyenovia's eye drug, Formosa Pharma says (Reuters)
Feb-13-24 07:00AM	Eyenovia Announces FDA Approval of Redwood City as Commercial Manufacturing Facility (GlobeNewswire) -5.76%
Jan-26-24 09:22AM	Formosa, fresh from Eyenovia deal, sells Brazilian rights to near-approval eye drug (FierceBiotech.com)
Jan-16-24 07:00AM	Eyenovia Re-Acquires Development and Commercialization Rights to MicroPine in the U.S. and Canada (GlobeNewswire) -7.51%
Dec-15-23 08:17AM	7 Promising Penny Stocks With the Potential to Defy Expectations (InvestorPlace)
Nov-14-23 10:38AM	Eyenovia, Inc. (NASDAQ:EYEN) Q3 2023 Earnings Call Transcript (Insider Monkey) +5.04%
Nov-13-23 04:05PM	Eyenovia Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Nov-06-23 08:00AM	Eyenovia to Report Third Quarter 2023 Results on Monday, November 13 (GlobeNewswire) -8.74%
Nov-02-23 07:00AM	Eyenovia Announces FDA Approval of Coastline International as Contract Manufacturer to Initiate Mydcombi Commercial Production (GlobeNewswire)
Oct-30-23 03:52PM	Billionaire Marc Lasrys Top 10 Stock Picks (Insider Monkey) +6.48%
07:00AM	Eyenovia to Sponsor Course on Drug Delivery Innovation at IJCAHPO's 51st Annual Continuing Education (ACE) Program (GlobeNewswire)
Oct-09-23 07:00AM	Eyenovia to Present Data on Preservative-Free Microbial Integrity of the Optejet (GlobeNewswire)
Sep-21-23 08:00AM	Eyenovia to Participate in Panel Discussion at Cantor Global Healthcare Conference (GlobeNewswire)
Sep-07-23 08:00AM	Eyenovia to Present at Upcoming H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-24-23 06:47PM	Eyenovia Announces $12 Million Registered Direct Offering (GlobeNewswire)
Aug-16-23 06:00AM	Eyenovia Acquires U.S. Commercial Rights to APP13007 (Clobetasol Propionate Ophthalmic Nanosuspension, 0.05%) from Formosa Pharmaceuticals (GlobeNewswire) -6.44%
Aug-14-23 09:05AM	Eyenovia, Inc. (NASDAQ:EYEN) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-11-23 06:08AM	Q2 2023 Eyenovia Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-10-23 04:05PM	Eyenovia Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Aug-09-23 08:00AM	Eyenovia to Present at Upcoming H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference (GlobeNewswire)
Aug-07-23 08:00AM	Eyenovia to Report Second Quarter 2023 Results on Thursday, August 10 (GlobeNewswire)
Aug-03-23 08:00AM	Eyenovia Announces First Commercial Sale of Mydcombi (GlobeNewswire)
Jun-26-23 08:00AM	Eyenovia Announces Addition to Russell 2000® and Russell 3000® Indexes (GlobeNewswire) -6.75%
Jun-06-23 09:00AM	Eyenovia Expands Its US Manufacturing Capabilities (ACCESSWIRE)
Jun-01-23 08:00AM	Eyenovia Announces Presentation at the OCTANE Ophthalmology Tech Forum 2023 (GlobeNewswire) +9.15%
May-12-23 06:04AM	Q1 2023 Eyenovia Inc Earnings Call (Thomson Reuters StreetEvents) -15.20%

Eyenovia, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of ophthalmology products. The company offers a piezo-print technology to deliver micro-doses of micro-therapeutics for the eyes. Its products include MicroProst, MicroStat, MicroTears, and MicroPine. The firm is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression, and mydriasis. The company was founded by Sean Ianchulev on March 12, 2014 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Rowe Michael M	Chief Executive Officer	Aug 28 '24	Buy	0.52	27,071	14,077	109,998	Aug 28 08:01 PM
Rowe Michael M	Chief Executive Officer	Aug 26 '24	Buy	0.57	50,000	28,500	82,927	Aug 27 01:06 PM
Grant Stuart M.	10% Owner	Jul 02 '24	Buy	0.66	1,515,151	1,000,000	10,914,153	Jul 03 03:18 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

EYEN

Eyenovia Inc

Upgrade your FINVIZ experience